Infographic on the Growth of Pharmaceutical Industry in India

The Indian pharmaceutical industry is projected to grow at a CAGR of over 10% to reach a size of US$ 130 billion by 2030.

Advantage India

Cost
Efficiency

India has emerged as the medial tourism hub of the world providing cost-effective treatments with the latest technology enabled by several pathbreaking reforms and provisions.​

Access to affordable HIV treatment from India is one of the greatest success stories in medicine. India is one of the biggest suppliers of low-cost vaccines in the world. ​

* Because of the low price and high quality, Indian medicines are preferred worldwide, thereby rightly making the country the ‘Pharmacy of the World’.​​

* India has been traditionally quite strong in the pharma sector, with a low cost of manufacturing (30%–35% lower than in the US and Europe), cost-efficient R&D (about 87% less than in developed markets), and cheap skilled labour​.

Cost Efficiency

Economic
Drivers

* The total market size of the Indian Pharma Industry is expected to reach US$ 130 billion by 2030 and US$ 450 billion market by 2047. ​

Indian pharmaceutical companies are projected to achieve a revenue growth of 9-11% in FY25. This growth is expected to be fueled by robust performances in key markets, including the United States, Europe, and emerging regions.​​

* India has the largest number of USFDA-compliant pharmaceutical plants outside the US and over 2,000 WHO-GMP approved facilities, serving demand from 150+ countries worldwide, with 10,500+ manufacturing facilities.​​

* India is emerging as a key player in the global pharmaceutical supply chain, with its CRDMO industry set to double to Rs. 1,21,282 crore (US$ 14 billion) by 2028, says Macquarie.​

* India's medical technology industry is poised to reach exports of up to US$ 20 billion (Rs. 1,69,000) by FY30, according to the CII.​

Economic Drivers

Policy
Support

* The Ministry's scheme “Strengthening of Pharmaceutical Industry (SPI)" with a total financial outlay of Rs. 500 crore (US$ 60.9 million) extends support required to existing pharma clusters and MSMEs across the country to improve their productivity, quality and sustainability. ​​

The Government has set a target to increase the number of Pradhan Mantri Bhartiya Jan Aushadhi Kendras to 10,500 by March 2025. The product basket of PMBJP comprises 1,451 drugs and 240 surgical instruments.​​

* The PLI scheme for pharmaceuticals is being implemented with a total outlay of the Rs. 15,000 crore (US$ 2.04 billion) spanning from 2020-21 to 2028-29, to boost India's manufacturing capacity, elevate investment, and diversify product offerings in the sector. ​

* The Indian government disbursed Rs. 604 crore (US$ 69.76 million) under the Production-Linked Incentive (PLI) scheme for the pharma sector during H1 of FY25.​

Policy Support

Increasing
Investment

* Up to 100%, FDI has been allowed through automatic route for Greenfield pharmaceuticals projects. For Brownfield pharmaceuticals projects, FDI allowed is up to 74% through automatic route and beyond that through government approval.​​

* The FDI equity inflow in the Drugs and Pharmaceuticals industry is Rs. 2,01,347 crore (US$ 23.04 billion) during the period April 2000-September 2024. ​

* The Union Budget 2025-26 proposes to allocate Rs. 5,268.72 crore (US$ 602.90 million) for the Department of Pharmaceuticals (DoP), around 28.8% higher than the Rs. 4,089.95 crore (US$ 468.01 million) Budget Estimates (BE) for the FY25. ​

Increasing Investment
Last updated: Apr, 2025

Major states for Pharmaceuticals

  • Karnataka
  • Maharashtra
  • Gujarat
  • Uttar Pradesh
  • Delhi NCR
  • Tamil Nadu
  • Telangana

Posters

MORE
Pharmaceutical Companies in India

Pharmaceutical Companies in India

Indian pharma company have won around 40 per cent of all Abbreviated New Drug Approval (ANDA) from the US Food and Drug Administration (FDA) between january and july 2013.

IBEF Campaigns

MORE
Discover India 2024

Discover India 2024

APEDA is organizing participation in SIAL Paris 2024 scheduled to be held f...

Aatmanirbhar Bharat Utsav 2024

Aatmanirbhar Bharat Utsav 2024

Union Minister of External Affairs, Dr. S. Jaishankar and Union Commerce an...

Case Studies

MORE

The Talent Tsunami: Harnessing India’s Demographic Dividend for Global Impact

The Talent Tsunami: Harnessing India’s Demographic Dividend for Global Impact

The demographic dividend has put India on the verge of change. Defined as the economic growth potential arising from a favourable age structure within...

The Future of Shipbuilding in India: Technological Innovations and Market Trends

The Future of Shipbuilding in India: Technological Innovations and Market Trends

The Indus Valley civilisation, which built early ships and traded internationally, is the source of India's rich maritime history. The shipbuildin...

Leading the Charge: EV Battery Recycling in India

Leading the Charge: EV Battery Recycling in India

The public and private sectors have invested significantly in electric vehicles (EVs) to lower carbon emissions and lessen reliance on fossil fuels, l...

IBEF BLOG

MORE
Regional Rural Banks: Strengthening Financial Inclusion and Driving Rural Development in India
9 Jul 2025

Regional Rural Banks: Strengthening Financial Inclusion and Driving Rural Development in India

Regional Rural Banks (RRBs) were established in 1975 to provide financial s...

The Podcasting Boom in India: Shaping the Future of Digital Storytelling
8 Jul 2025

The Podcasting Boom in India: Shaping the Future of Digital Storytelling

Podcasts are transforming into an important segment for digital media in In...

The Rise of Agrivoltaics: Combining Solar Power with Farming in India
3 Jul 2025

The Rise of Agrivoltaics: Combining Solar Power with Farming in India

The agricultural sector in India employs 42.3% of the population, contribut...

Partners
Loading...